UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of July 2025
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Transaction in own shares
GSK plc (the "Company") announces today acting
through its corporate stockbroker, Merrill Lynch International (the
"Broker"), it has purchased the following number of the
Company's ordinary shares of 31¼ pence
each.
|
Date of purchase:
|
18 July 2025
|
|
Aggregate number of ordinary shares of 31¼ pence
each purchased:
|
505,771
|
|
Lowest price paid per share (GBp):
|
1,319.00p
|
|
Highest price paid per share (GBp):
|
1,360.50p
|
|
Volume-weighted average price paid per share (GBp):
|
1,344.42p
|
The purchased shares will be held as Treasury shares.
Such purchase forms part of the Company's existing buyback
programme and was effected pursuant to the non-discretionary
agreement entered into with the Broker on 4 June 2025, as announced
on 4 June 2025. Since 4 June 2025 the Company has purchased
14,683,084 ordinary shares.
Following the above purchase, the Company will hold 232,817,467
ordinary shares in treasury and have 4,082,566,813 ordinary shares
in issue (excluding Treasury shares).
The total number of voting rights in the Company
is 4,082,566,813.
This figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
Company under the Financial Conduct Authority's Disclosure Guidance
and Transparency Rules.
The Company confirms that, in accordance with DTR 5.5.1R, following
the above purchase the percentage of voting rights attributable to
the ordinary shares held in treasury is 5.70 per
cent.
Detailed information of the individual trades made by the Broker on
the London Stock Exchange and the CBOE Europe Limited recognised
investment exchange (through its order books having market
identification codes CHIX or BATE) as part of the buyback programme
can be found at:
http://www.rns-pdf.londonstockexchange.com/rns/7518R_1-2025-7-18.pdf
Ends
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
|
|
|
|
Investor Relations:
|
Constantin Fest
|
+44 (0) 7831 826525
|
(London)
|
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
|
Steph Mountifield
|
+44 (0) 7796 707505
|
(London)
|
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
|
Frannie DeFranco
|
+1 215 751 3126
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the "Risk
Factors" section in GSK's Annual Report on Form 20-F for 2024, and
GSK's Q1 Results for 2025.
Registered in England & Wales:
No.
3888792
Registered Office:
79
New Oxford Street
London
WC1A
1DG
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date:
July 21, 2025
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|